Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Advanced 37.3% over 21 sessions to a period high. Q2 2026 XDEMVY sales grew more than 69% year over year to $173.9 million, while the planned Alkeus acquisition, positive TEASE-1 results, and a $125 million PIPE provide commercial, pipeline, and liquidity catalysts.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Improving Cash Flow ⢠Persistent Losses TARS has strong liquidity and improving cash flow, but persistent losses, accumulated deficits, low efficiency, and a high valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong upward trend ⢠Overbought momentum ⢠Critical nearby support Support Level: $82.76â$83.21; deeper support $74.00â$75.00 Resistance Level: $90.00â$91.00 TARS surged about 40% over the last month to fresh highs near $90.78, but its overbought RSI (~85) raises pullback risk unless $82.76â$83.21 support holds.
Sentiment & News
Key News Insights: ⢠XDEMVY Sales Surge ⢠Alkeus Deal Closed ⢠Loss Miss Tarsus posted surging XDEMVY sales and strengthened its pipeline through the Alkeus acquisition, though wider-than-expected losses remain a near-term risk.
AI Summary
TARS has evolved into a cash-generating ophthalmology platform, but after its sharp rally investors should prioritize evidence that XDEMVY's high-margin growth converts into durable operating profit while Alkeus/gildeuretinol adds option value without renewed dilution or execution strain.
Description
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for ophthalmic and related conditions. Its lead candidate, TP-03, is in Phase III for blepharitis associated with Demodex infestation and for meibomian gland disease, while additional pipeline programs include treatments for rosacea, Lyme prophylaxis, and malaria reduction. The company also develops the lotilaner molecule for use across eye care, dermatology and other human medicine indications and is headquartered in Irvine, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | TARS | Tarsus Pharmaceuticals, Inc. | Advanced 37.3% over 21 sessions to a period high. Q2 2026 XDEMVY sales grew more than 69% year over year to $173.9 million, while the planned Alkeus acquisition, positive TEASE-1 results, and a $125 million PIPE provide commercial, pipeline, and liquidity catalysts. | Closed | -2.5% |